Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTOR
stocks logo

CTOR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.110
sliders
Low
6.00
Averages
6.00
High
6.00
Current: 1.110
sliders
Low
6.00
Averages
6.00
High
6.00
Maxim
Michael Okunewitch
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Michael Okunewitch
Price Target
$6
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim analyst Michael Okunewitch upgraded Citius Oncology to Buy from Hold with a $6 price target.
Maxim
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Price Target
$6
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim upgraded Citius Oncology to Buy from Hold with a $6 price target. The company has taken key steps to address its capital needs and now should have a path to launching Lymphir in Q4 of this year, which is a "key event" for Citius, the analyst tells investors in a research note. Cutaneous T-cell lymphoma is a relatively small and concentrated market, which should support pricing of about $300K per course of treatment, and the firm believes that sales could "ramp quickly" in 2026, the firm added.
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim
Price Target
2025-05-23
downgrade
Buy
to
Hold
Reason
Maxim downgraded Citius Oncology to Hold from Buy.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Citius Oncology Inc (CTOR.O) is -18.50, compared to its 5-year average forward P/E of -0.98. For a more detailed relative valuation and DCF analysis to assess Citius Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.98
Current PE
-18.50
Overvalued PE
22.69
Undervalued PE
-24.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.52
Current PS
0.00
Overvalued PS
3.57
Undervalued PS
-0.53
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CTOR News & Events

Events Timeline

(ET)
2025-12-04
08:40:00
Citius Oncology Signs Exclusive Distribution Agreement with Er-Kim
select
2025-12-01 (ET)
2025-12-01
12:10:00
Citius Oncology Launches LYMPHIR for Skin T-Cell Lymphoma Treatment
select
2025-11-21 (ET)
2025-11-21
08:40:30
Citius Oncology to expedite Lymphir launch by incorporating Verix AI technology
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04PRnewswire
Citius Oncology Partners with Er-Kim for Exclusive LYMPHIR Distribution in GCC Countries
  • Market Expansion: Citius Oncology's exclusive distribution agreement with Turkey's Er-Kim significantly enhances access to LYMPHIR across Turkey and six Gulf Cooperation Council countries, expanding its reach to a total of 19 international markets, which is expected to meet the urgent demand for innovative oncology treatments in the region.
  • Strategic Partnership: Leveraging Er-Kim's extensive experience in complex international markets, the company will manage sales, marketing, and reimbursement activities for LYMPHIR, ensuring successful implementation in emerging markets and enhancing Citius Oncology's competitiveness in the global oncology landscape.
  • Product Supply: Under the agreement, Citius Oncology will supply finished LYMPHIR products and support Er-Kim's marketing efforts, accelerating the drug's penetration into new markets and potentially driving revenue growth for the company.
  • Commitment to Innovation: This partnership underscores Citius Oncology's dedication to broadening access to innovative oncology therapies through strategic collaborations with experienced global partners, further solidifying its position in the international market.
[object Object]
Preview
5.0
12-02NASDAQ.COM
Citius Oncology Introduces LYMPHIR, The First New Systemic Treatment for CTCL in More Than Seven Years

  • Launch of LYMPHIR: Citius Oncology has launched LYMPHIR, an immunotherapy for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL), marking the first FDA-approved systemic therapy for this condition in over seven years.

  • Clinical Efficacy: The FDA approval was based on Pivotal Study 302, which showed a 36.2% Objective Response Rate and significant relief from severe itching, with a median time to response of just 1.4 months and no cumulative toxicity.

  • Market Potential: LYMPHIR enters a U.S. market valued at over $400 million, with opportunities for international expansion and potential label extensions, as Citius focuses on ensuring the therapy reaches patients in need.

  • Company Insights: Citius executives highlighted the importance of LYMPHIR in addressing a significant clinical need in CTCL treatment, with expectations for it to enhance shareholder value and improve patient quality of life.

[object Object]
Preview
5.0
12-02PRnewswire
Citius Oncology Launches LYMPHIR, Addressing CTCL Treatment Gap
  • New Drug Launch: Citius Oncology announces the nationwide launch of LYMPHIR™ (denileukin diftitox-cxdl) in the U.S., filling a critical treatment gap for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in a market valued at over $400 million, addressing a clear clinical need.
  • Significant Clinical Efficacy: In Phase 3 trials, LYMPHIR demonstrated an Objective Response Rate (ORR) of 36.2%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, highlighting its potential to improve patient quality of life.
  • Rapid Response Time: The median time to response for LYMPHIR is 1.4 months, providing patients with quick skin relief, marking a significant advancement for Citius Oncology in the CTCL treatment landscape.
  • International Market Expansion: Citius Oncology has signed a distribution agreement with Integris Pharma S.A. to initiate named-patient access programs in Greece, Cyprus, and other Southern European and Balkan countries, enhancing global patient access to LYMPHIR.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Citius Oncology Inc (CTOR) stock price today?

The current price of CTOR is 1.11 USD — it has decreased -9.02 % in the last trading day.

arrow icon

What is Citius Oncology Inc (CTOR)'s business?

Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

arrow icon

What is the price predicton of CTOR Stock?

Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Citius Oncology Inc (CTOR)'s revenue for the last quarter?

Citius Oncology Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Citius Oncology Inc (CTOR)'s earnings per share (EPS) for the last quarter?

Citius Oncology Inc. EPS for the last quarter amounts to -0.08 USD, decreased -300.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Citius Oncology Inc (CTOR)'s fundamentals?

The market is revising No Change the revenue expectations for Citius Oncology, Inc. (CTOR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -40.96%.
arrow icon

How many employees does Citius Oncology Inc (CTOR). have?

Citius Oncology Inc (CTOR) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Citius Oncology Inc (CTOR) market cap?

Today CTOR has the market capitalization of 92.70M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free